European CHMP recommends license extension of nintedanib (Ofev)
The license extension is in adults for the treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype.
Source:
European Medicines Agency
The license extension is in adults for the treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype.
European Medicines Agency